Skip to content

Erasca, Inc. ERAS Current ratio

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Eli Lilly logo
Eli LillyLLY
1.5×+0.1×
Pfizer logo
PfizerPFE
1.2×0.0×
Amgen logo
AmgenAMGN
1.3×+0.1×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
6.8×-6.7×
Tango Therapeutics logo
Tango TherapeuticsTNGX
27.4×+21.1×

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s current ratio?
Erasca, Inc. (ERAS) reported current ratio of 9.5× in Q1 2026.
How has Erasca, Inc.'s current ratio changed year-over-year?
Erasca, Inc.'s current ratio decreased by 22.9% year-over-year, from 12.4× to 9.5×.
What is the long-term trend for Erasca, Inc.'s current ratio?
Over 5 years (2020 to 2025), Erasca, Inc.'s current ratio has grown at a 2.7% compound annual growth rate (CAGR), from 8.8× to 10×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.